Fennec Pharmaceuticals Inc. FRX.TO
Set alert
14.79 CAD -0.04 -0.27%
As of Nov 2, 3:54 PM ET
13.79 Day range 14.79
7.59 52-week range 17.64
- YTD
- +39.53%
- 1 year
- +27.61%
- Open
- 13.79
- Prev close
- 14.83
- Mkt cap
- 518.64M
- Vol
- 889
- Avg vol
- 462
- EPS
- -0.17
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.79
- High
- 14.79
- Forward P/E
- 0.00
- Beta
- 0.27
- Short ratio
- 7.66
- Inst. own
- 54.70%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 7.13
- 200-d avg
- 9.13
- 1y target
- 0.00
2Y chart
Events in this range
- Dec 17, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (83)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 21, 2026 | 2 months ago |
| RSI: Overbought | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| RSI: Overbought | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
| SMA: Bearish | Jul 30, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 9, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 23, 2026 | 4 months ago |
| RSI: Overbought | Jun 23, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 3, 2026 | 5 months ago |
| RSI: Overbought | Jun 2, 2026 | 5 months ago |
| SMA: Bullish | May 14, 2026 | 5 months ago |
| SMA: Bullish | May 14, 2026 | 5 months ago |
| RSI: Overbought | May 14, 2026 | 5 months ago |
| SMA: Bearish | May 13, 2026 | 5 months ago |
Newest 20 of 83.
Key statistics
- Market cap
- 244.42M
- Enterprise value
- 226.88M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 4.95
- Price / book
- 0.00
- EPS (TTM)
- -0.06
- Beta
- 0.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -2.30%
- Revenue (TTM)
- 49.35M
- Revenue growth
- 7.00%
- Free cash flow
- -3.40M
- Total cash
- 40.32M
- Total debt
- 32.10M
- Return on equity
- 0.00%
- Shares outstanding
- 27.43M
- Short % of float
- 0.13%
- 50-day average
- 7.13
- 200-day average
- 9.13
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 0.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.2538.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 22, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 14, 2024 | Craig-Hallum | main | Buy | Buy |
| May 15, 2024 | Craig-Hallum | main | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 4, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fennecpharma.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on FRX.TO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDRADE ROBERT C | Chief Financial Officer | Stock Award(Grant) | Dec 1, 2024 | 128,423 |
| HAIGH ADRIAN J | Chief Operating Officer | Sale | Apr 21, 2024 | 0 |
| ISLAM KHALID | Director | Conversion of Exercise of derivative security | Nov 15, 2023 | 213,825 |
| RALLIS CHRISTOPHER ANIGERON | Director | Sale | Dec 1, 2024 | 52,214 |
| RAYKOV ROSTISLAV CHRISTOV | Director | Sale | Dec 4, 2024 | 66,432 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Southpoint Capital Advisors Lp | 14.84% | 4,077,214 | 36.33M | Sep 29, 2024 |
| Sonic Gp LLC | 8.76% | 2,407,357 | 21.45M | Sep 29, 2024 |
| Solas Capital Management, LLC | 7.00% | 1,923,536 | 17.14M | Sep 29, 2024 |
| DG Capital Management, LLC | 5.54% | 1,522,204 | 13.56M | Sep 29, 2024 |
| Blackrock Inc. | 4.48% | 1,229,477 | 10.95M | Sep 29, 2024 |
| Vanguard Group Inc | 3.81% | 1,047,891 | 9.34M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.19% | 876,208 | 7.81M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.04% | 559,371 | 4.98M | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.88% | 241,018 | 2.15M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.60% | 165,510 | 1.47M | Oct 30, 2024 |
| Vanguard Russell 2000 Index Fund | 0.34% | 94,580 | 842.71K | Aug 30, 2024 |
| Schwab Capital Trust-Small Cap Index Fund | 0.20% | 55,452 | 494.08K | Jul 30, 2024 |